EMP2: Ethyl-Methyl, di Methyl, tri Methyl Pyruvate Acid Esters: A Tool for Regulating HbA1c and a Riboswitch Activator

Abstract

The invention is a novel series of compounds represented by general formula, its analogs, tautomeric forms, stereoisomers, pharmaceutically acceptable salts and polymorphs wherein said compound described is a group of antisense molecules possessing immediate global cellular penetration due to their molecular structure and lipophilicity. The molecules are combinations of ethyl and methyl pyruvates. They induce riboswitch activity and reduce target RNA and nucleic acids such as HbA1c. They reduce inflammation and enhance energy production. These features improve therapeutic outcomes of diabetes, neuropathy and cellular aging.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 521 / 747 titled “EMP2: Ethyl-Methyl, di Methyl, tri Methyl Pyruvate Acid Esters: A Tool for Regulating HbA1c and a Human Riboswitch Activator” field Aug. 09, 2011 at 23:33:42 EST, which is hereby incorporated by reference in its entirety.FIELD OF INVENTION[0002]This present invention describes a short systemic and antisense compound. Included are such compounds comprising chemically combined moieties of ethyl and methyl, di Methyl, tri Methyl pyruvic acid esters. Said compound is chemically combined in such a manner as to retain the individual properties of each separately and utilize the combinatorial valency and synergy of joining the two. Such a short targeted compound is useful for the reduction of target nucleic acids and / or proteins such as HbA 1 c, high-affinity nucleotide modifications useful for reducing a target RNA in vivo, in tissues, animals and humans w...

AI Technical Summary

Benefits of technology

This patent describes a new invention that uses ethyl pyruvate and methylated pyruvates to treat targeted molecules in the body. These molecules have the ability to penetrate cell membranes and work together to release over time in the inner mitochondria, where they can improve therapeutic outcomes by reducing targeted molecules and proteins like HbA1c. The invention also reboots all intracellular functions, upgrading them with enhanced intracellular crosstalk and signaling. By doing so, it improves glucose control and disables the genome from being damaged. The invention also has pharmaceutical effects, such as reducing inflammation, and can lead to the creation of new molecules that regulate gene expression and improve cellular function. Overall, this patent demonstrates how ethyl pyruvate and methylated pyruvates can be used to improve therapeutic outcomes and treat targeted molecules in the body.

Problems solved by technology

Diseases such as type II diabetes (DM2) are caused by insufficient energy required to continuously maintain the structure and function in cells.

Finally, cytosolic and nuclear components are malfunctioning, and are in need of repair or replacement.